Literature DB >> 24644033

Mice expressing mutant Trpv4 recapitulate the human TRPV4 disorders.

Michael M Weinstein1,2, Stuart W Tompson1, Yuqing Chen3, Brendan Lee3, Daniel H Cohn1,2.   

Abstract

Activating mutations in transient receptor potential vanilloid family member 4 (Trpv4) are known to cause a spectrum of skeletal dysplasias ranging from autosomal dominant brachyolmia to lethal metatropic dysplasia. To develop an animal model of these disorders, we created transgenic mice expressing either wild-type or mutant TRPV4. Mice transgenic for wild-type Trpv4 showed no morphological changes at embryonic day 16.5 but did have a delay in bone mineralization. Overexpression of a mutant TRPV4 caused a lethal skeletal dysplasia that phenocopied many abnormalities associated with metatropic dysplasia in humans, including dumbbell-shaped long bones, a small ribcage, abnormalities in the autopod, and abnormal ossification in the vertebrae. The difference in phenotype between embryos transgenic for wild-type or mutant Trpv4 demonstrates that an increased amount of wild-type protein can be tolerated and that an activating mutation of this protein is required to produce a skeletal dysplasia phenotype.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CALCIUM CHANNEL; METATROPIC DYSPLASIA; SKELETAL DYSPLASIA; SMDK; TRANSGENIC MICE; TRPV4

Mesh:

Substances:

Year:  2014        PMID: 24644033      PMCID: PMC4108531          DOI: 10.1002/jbmr.2220

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

1.  Analysis of the native quaternary structure of vanilloid receptor 1.

Authors:  N Kedei; T Szabo; J D Lile; J J Treanor; Z Olah; M J Iadarola; P M Blumberg
Journal:  J Biol Chem       Date:  2001-05-17       Impact factor: 5.157

2.  Novel and recurrent TRPV4 mutations and their association with distinct phenotypes within the TRPV4 dysplasia family.

Authors:  J Dai; O-H Kim; T-J Cho; M Schmidt-Rimpler; H Tonoki; K Takikawa; N Haga; K Miyoshi; H Kitoh; W-J Yoo; I-H Choi; H-R Song; D-K Jin; H-T Kim; H Kamasaki; P Bianchi; G Grigelioniene; S Nampoothiri; M Minagawa; S-i Miyagawa; T Fukao; C Marcelis; M C E Jansweijer; R C M Hennekam; F Bedeschi; A Mustonen; Q Jiang; H Ohashi; T Furuichi; S Unger; B Zabel; E Lausch; A Superti-Furga; G Nishimura; S Ikegawa
Journal:  J Med Genet       Date:  2010-06-24       Impact factor: 6.318

3.  Spondylo-epiphyseal dysplasia, Maroteaux type (pseudo-Morquio syndrome type 2), and parastremmatic dysplasia are caused by TRPV4 mutations.

Authors:  Gen Nishimura; Jin Dai; Ekkehart Lausch; Sheila Unger; André Megarbané; Hiroshi Kitoh; Ok Hwa Kim; Tae-Joon Cho; Francesca Bedeschi; Francesco Benedicenti; Roberto Mendoza-Londono; Margherita Silengo; Maren Schmidt-Rimpler; Jurgen Spranger; Bernhard Zabel; Shiro Ikegawa; Andrea Superti-Furga
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

4.  Developmental acquisition of type X collagen in the embryonic chick tibiotarsus.

Authors:  T M Schmid; T F Linsenmayer
Journal:  Dev Biol       Date:  1985-02       Impact factor: 3.582

5.  Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasia.

Authors:  Natalia Camacho; Deborah Krakow; Sharlin Johnykutty; Philip J Katzman; Samuel Pepkowitz; Joris Vriens; Bernd Nilius; Brendan F Boyce; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

6.  Mutations in TRPV4 cause an inherited arthropathy of hands and feet.

Authors:  Shireen R Lamandé; Yuan Yuan; Irma L Gresshoff; Lynn Rowley; Daniele Belluoccio; Kumara Kaluarachchi; Christopher B Little; Elke Botzenhart; Klaus Zerres; David J Amor; William G Cole; Ravi Savarirayan; Peter McIntyre; John F Bateman
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

7.  Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia.

Authors:  Deborah Krakow; Joris Vriens; Natalia Camacho; Phi Luong; Hannah Deixler; Tara L Funari; Carlos A Bacino; Mira B Irons; Ingrid A Holm; Laurie Sadler; Ericka B Okenfuss; Annelies Janssens; Thomas Voets; David L Rimoin; Ralph S Lachman; Bernd Nilius; Daniel H Cohn
Journal:  Am J Hum Genet       Date:  2009-02-19       Impact factor: 11.025

Review 8.  The vanilloid transient receptor potential channel TRPV4: from structure to disease.

Authors:  Wouter Everaerts; Bernd Nilius; Grzegorz Owsianik
Journal:  Prog Biophys Mol Biol       Date:  2009-10-14       Impact factor: 3.667

Review 9.  TRPV4-associated skeletal dysplasias.

Authors:  Gen Nishimura; Ekkehart Lausch; Ravi Savarirayan; Masahiro Shiba; Juergen Spranger; Bernhard Zabel; Shiro Ikegawa; Andrea Superti-Furga; Sheila Unger
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-07-12       Impact factor: 3.908

10.  Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C.

Authors:  Guida Landouré; Anselm A Zdebik; Tara L Martinez; Barrington G Burnett; Horia C Stanescu; Hitoshi Inada; Yijun Shi; Addis A Taye; Lingling Kong; Clare H Munns; Shelly S Choo; Christopher B Phelps; Reema Paudel; Henry Houlden; Christy L Ludlow; Michael J Caterina; Rachelle Gaudet; Robert Kleta; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  Nat Genet       Date:  2009-12-27       Impact factor: 38.330

View more
  10 in total

1.  Somatic mosaicism for a lethal TRPV4 mutation results in non-lethal metatropic dysplasia.

Authors:  Michael M Weinstein; Taekyu Kang; Ralph S Lachman; Michael Bamshad; Deborah A Nickerson; Deborah Krakow; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2016-08-17       Impact factor: 2.802

Review 2.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

3.  The transcriptional cofactor Jab1/Cops5 is crucial for BMP-mediated mouse chondrocyte differentiation by repressing p53 activity.

Authors:  Murali K Mamidi; William E Samsa; Lindsay A Bashur; Yuqing Chen; Ricky Chan; Brendan Lee; Guang Zhou
Journal:  J Cell Physiol       Date:  2021-01-03       Impact factor: 6.513

4.  Genes uniquely expressed in human growth plate chondrocytes uncover a distinct regulatory network.

Authors:  Bing Li; Karthika Balasubramanian; Deborah Krakow; Daniel H Cohn
Journal:  BMC Genomics       Date:  2017-12-20       Impact factor: 3.969

5.  Novel TRPV4 variant causes a severe form of metatropic dysplasia.

Authors:  Lise Graversen; Annette Haagerup; Brian N Andersen; Karin K Petersen; Vibike Gjørup; Gudrun Gudmundsdottir; Ida Vogel; Pernille A Gregersen
Journal:  Clin Case Rep       Date:  2018-07-20

6.  Protein informatics combined with multiple data sources enriches the clinical characterization of novel TRPV4 variant causing an intermediate skeletal dysplasia.

Authors:  Stephanie L Hines; John E Richter; Ahmed N Mohammad; Jain Mahim; Paldeep S Atwal; Thomas R Caulfield
Journal:  Mol Genet Genomic Med       Date:  2019-01-28       Impact factor: 2.183

Review 7.  Dental Pulp-Derived Mesenchymal Stem Cells for Modeling Genetic Disorders.

Authors:  Keiji Masuda; Xu Han; Hiroki Kato; Hiroshi Sato; Yu Zhang; Xiao Sun; Yuta Hirofuji; Haruyoshi Yamaza; Aya Yamada; Satoshi Fukumoto
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

8.  Unraveling the mechanism by which TRPV4 mutations cause skeletal dysplasias.

Authors:  Holly A Leddy; Amy L McNulty; Farshid Guilak; Wolfgang Liedtke
Journal:  Rare Dis       Date:  2014-10-30

9.  New therapeutic targets in rare genetic skeletal diseases.

Authors:  Michael D Briggs; Peter A Bell; Michael J Wright; Katarzyna A Pirog
Journal:  Expert Opin Orphan Drugs       Date:  2015-09-24       Impact factor: 0.694

Review 10.  The Regulation of Growth in Developing, Homeostatic, and Regenerating Tetrapod Limbs: A Minireview.

Authors:  Kaylee M Wells; Mary Baumel; Catherine D McCusker
Journal:  Front Cell Dev Biol       Date:  2022-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.